SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing intense market volatility and significant analyst downgrades following a weak bookings guidance reset and the disruptive impact of its new age verification rollout. The community remains deeply polarized, with many investors debating whether the current selloff offers a buying opportunity in a sticky platform or if persistent safety concerns and slowing growth justify further downside.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending following the announcement of a $30 million private placement and a new licensing deal for an anti-IgE asset, which has triggered intense speculation regarding its potential for a short squeeze among retail traders. While some investors are highlighting the company's clinical pipeline and low float as catalysts for a major rally, others remain skeptical, pointing to the effective offering price and potential dilution risks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors digest a massive earnings beat, with the community actively debating whether the company's strong monetization and user growth can spark a sustained rally or if the stock will face typical post-earnings volatility. While bulls point to improved profitability and long-term data licensing potential as catalysts for a squeeze, bears remain skeptical, citing concerns over user engagement quality and historical patterns of post-report pullbacks.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing significant bullish momentum driven by the upcoming presentation of its pancreatic cancer trial data at Digestive Disease Week, which has investors anticipating a major clinical breakthrough. Community sentiment remains overwhelmingly optimistic, with retail traders aggressively accumulating shares and discussing potential catalystsincluding trial expansions and upcoming gala eventsas the stock continues to trend on high volume.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility and a parabolic rally driven by a extremely low tradeable float, which has triggered an aggressive short squeeze as borrow fees have surged toward 1000%. The community is intensely debating the sustainability of this run, with many bullish traders focused on momentum and the potential for forced short covering, while skeptics point to the company's history of reverse splits and warn of an inevitable correction.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is seeing significant market activity following a record-breaking fiscal quarter that featured double-digit revenue growth and a new $100 billion share buyback authorization. Investors are actively debating the leadership transition to incoming CEO John Ternus and the company's long-term growth outlook, with community discussion centered on supply chain constraints, margin pressure from memory costs, and anticipation for upcoming AI product reveals.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing extreme volatility following a massive quarterly earnings beat that saw revenue triple and guidance raised, with the community divided between bulls viewing the pullback as a gift and bears warning of a potential bubble after a year of historic gains. Investors are closely monitoring the $6 billion share buyback announcement and the company's aggressive expansion into AI data center infrastructure as key indicators for whether the stock can maintain its upward trajectory.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is facing intense downward pressure and community criticism following the announcement of an $80 million capital raise through a common stock and pre-funded warrant offering. Investors are actively debating the company's management execution and the potential for further dilution, as the stock struggles to find footing amidst recurring concerns over the firm's long-term business model.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging following a major $950 million patent settlement that removes significant litigation overhang and allows investors to refocus on its promising oncology and respiratory pipeline. Community sentiment is highly energized as institutional accumulation grows, with many traders anticipating that the resolution of these legal hurdles paves the way for further upside momentum.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is attracting significant investor attention following a powerful earnings report where it beat revenue expectations and raised guidance, highlighting the success of its AI-driven Athena platform. The community is actively debating the stock's potential for a short squeeze and its long-term growth prospects, with many bulls emphasizing its consistent beat-and-raise history as evidence of strong operational execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The financing uses a single-asset SPV, allowing BioAtla to fund a pivotal study without a broader equity raise.</li><li>BioAtla retains majority ownership of Oz-V, keeping 65% control across solid tumor indications after the transaction closes.</li><li>Phase 3 enrollment is expected to begin in early 2026.</li></ul>Shares of BioAtla Inc. (BCAB) slipped nearly 4% in premarket trading on Wednesday after early gains faded, as investors weighed the structure of the company’s $40 million special purpose vehicle (SPV) financing to advance its lead cancer program.<h2 class="st-heading-2">SPV Deal Funds Late-Stage Trial</h2>BioAtla said the SPV transaction with GATC Health Corp. is designed to fund a registrational Phase 3 trial of ozuriftamab vedotin (Oz-V) in patients whose oropharyngeal cancer has progressed after prior treatments.&nbsp;The company will receive an initial $5 million to support general operations and trial expenses, with the remaining $35 million expected to close in the first quarter of 2026 as the study begins.Following completion, BioAtla will retain 65% ownership of Oz-V across all solid tumor indications, while the SPV, backed by Inversagen AI LLC, will hold the remaining 35%.<h2 class="st-heading-2">Investor Focus On Structure</h2>The single-asset SPV approach allows BioAtla to fund a pivotal trial without a broader equity raise, but the structure appeared to draw a cautious response from investors after the initial premarket rally. Under the arrangement, the SPV will share in future development and commercialization economics for Oz-V.<h2 class="st-heading-2">Phase 3 Path&nbsp;</h2>BioAtla will lead execution of the Phase 3 study, with patient enrollment expected to begin in early 2026.&nbsp;The company said the trial is intended to support a potential accelerated approval pathway in the U.S. Oz-V has received Fast Track designation from the FDA for recurrent or metastatic squamous cell carcinoma of the head and neck.<h2 class="st-heading-2">BioAtla Retains Lead Role On Oz-V</h2>The company said the financing provides a near-term path to advance Oz-V while preserving majority ownership, and noted ongoing discussions around expanding the drug’s use into other HPV-positive solid tumors, including cervical cancer.&nbsp;BioAtla and GATC Health also expect to collaborate with Inversagen AI on additional research tied to senescence and longevity technologies, with BioAtla retaining rights for cancer applications.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for BioAtla was ‘bearish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:973/141;" src="https://news.stocktwits-cdn.com/bcab_ss_png_1ab7393b71.webp" alt="bcab ss.png" width="973" height="141"><figcaption>BCAB sentiment and message volume as of December 31| Source: Stocktwits</figcaption></figure>One user said the market had yet to fully price in the $40 million upfront component of the deal.<stembedurl>https://stocktwits.com/BiotechValues/message/640486061</stembedurl>Another user said the deal fell short of a true global license agreement, pointing instead to the SPV structure and its terms.<stembedurl>https://stocktwits.com/SDBiotechInvestor/message/640485518</stembedurl><a href="https://stocktwits.com/symbol/BCAB">BioAtla’s stock</a> has risen 21% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAtla logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial

The company disclosed the terms and timeline of an SPV arrangement tied to its Oz-V development program.

Equity

Big short fame Michael Burry-run Scion Asset Management’s September quarter 13F <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1649339/000090514824003106/xslForm13F_X02/informationtable.xml">report</a> filed late Thursday showed increased exposure to its China stock holdings Alibaba Group Holding Ltd. (<a class="mention" data-mention="$BABA" data-symbol-id="BABA" href="https://stocktwits.com/symbol/BABA" target="_blank">$BABA</a>), Baidu, Inc. (<a class="mention" data-mention="$BIDU" data-symbol-id="BIDU" href="https://stocktwits.com/symbol/BIDU" target="_blank">$BIDU</a>) and JD.com. Inc. (<a class="mention" data-mention="$JD" data-symbol-id="JD" href="https://stocktwits.com/symbol/JD" target="_blank">$JD</a>). The hedge-fund manager, however, covered much of his positions in these stocks with put options.&nbsp;Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.At the end of the third quarter, Scion held 200,000 Alibaba ADRs valued at $21.22 million, up from 155,000 ADRs worth $11.16 million at the end of the second quarter.He hedged his Alibaba bet by buying put options on 168,900 ADRs. This strategy insulates him against any potential drop in Alibaba shares.&nbsp;Alibaba shares have rebounded nicely this year amid China’s concerted efforts to stimulate domestic growth. The e-commerce giant is scheduled to report its second-quarter results before the market opens on Friday.Burry’s firm increased its Baidu holding from 75,000 ADRs, valued at $6.49 million, to 125,000 ADRs worth $13.16 million. It also bought put options on 83,000 Baidu ADRs.The firm loaded up ADRs of Alibaba’s peer JD, increasing its stake in the company from 250,000 ADRs to 500,000 ADRs. The value of JD,com holdings swelled from $6.46 million to $20 million. Bury also bought puts on JD.com for 500,000 in underlying shares.On the other hand, Burry halved RealReal, Inc. (<a class="mention" data-mention="$REAL" data-symbol-id="REAL" href="https://stocktwits.com/symbol/REAL" target="_blank">$REAL</a>) holdings from 1 million shares to 500,00 shares. It also significantly cut its stake in&nbsp;American Coastal Insurance Corporation (<a class="mention" data-mention="$ACIC" data-symbol-id="ACIC" href="https://stocktwits.com/symbol/ACIC" target="_blank">$ACIC</a>) from 251,892 to 100,000.Scion fully cashed out of oncology-focused biotech BioAtla, Inc. (<a class="mention" data-mention="$BCAB" data-symbol-id="BCAB" href="https://stocktwits.com/symbol/BCAB" target="_blank">$BCAB</a>) and office real estate investment trust Hudson Pacific Properties, Inc. (<a class="mention" data-mention="$HPP" data-symbol-id="HPP" href="https://stocktwits.com/symbol/HPP" target="_blank">$HPP</a>).On Stocktwits, sentiment towards Burry’s China holdings is muted.&nbsp;Sentiment toward Alibaba was 'neutral' on Stocktwits platform, although improving from a 'bearish' stance a day ago.<figure class="image"><a href="https://stocktwits.com/symbol/BABA"><img style="aspect-ratio:632/133;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/baba_bury_sentiment_76d1568b0e.png" alt="baba-bury-sentiment.png" width="632" height="133"></a><figcaption>BABA sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>&nbsp;JD.com elicited 'bearish sentiment' (36/100) from the retail, although message activity remained 'extremely high,' possibly due to the earnings report released Thursday.<figure class="image"><a href="https://stocktwits.com/symbol/JD"><img style="aspect-ratio:630/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/jd_sentiment_cffa43fe76.png" alt="jd-sentiment.png" width="630" height="135"></a><figcaption>JD sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Baidu did not fare any better, with the retail mood 'bearish' (45/100) on Stocktwits, although message volume, a proxy for activity, was 'high.'<figure class="image"><a href="https://stocktwits.com/symbol/BIDU"><img style="aspect-ratio:632/140;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bidu_sentiment_fb301f5932.png" alt="bidu-sentiment.png" width="632" height="140"></a><figcaption>BIDU sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>As of 4:06 am ET, Alibaba shares eased 0.63% to $90.01, while JD.com climbed 1.83% to $33.96 and Baidu gained 1.18% to $85.05.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-s-berkshire-initiates-positions-in-domino-s-pizza-pool-corp-does-retail-share-the-sentiment/cJ4F7DqRfp">Warren Buffett’s Berkshire Initiates Positions In Domino’s Pizza, Pool Corp: Does Retail Share The Sentiment?</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Chinese stocks are seeing green shoots of recovery amid stimulus measures to reinvigorate growth.

Michael Burry Cautiously Ups Alibaba, JD.com, Baidu Bets With Offsetting Hedges: Retail Doesn’t Share Big Short Investor’s Optimism

Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

BCAB
BioAtla Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCAB News

BCABBioAtla Inc